Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.
Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- CheckyesterdayChange DetectedLocation entry changed from Tainan City, Taiwan, 70403 to Tainan, Taiwan, 70403; the government funding lapse notice banner was removed.SummaryDifference0.3%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe differences are minor UI and formatting adjustments to the Study Details page without changes to core study data such as eligibility criteria, primary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check29 days agoChange DetectedMinor metadata update: the citation’s online-ahead-of-print note and date formatting were adjusted; core study information remains the same.SummaryDifference0.6%
- Check44 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%
- Check51 days agoChange DetectedUpgrade version from v3.0.2 to v3.1.0. No other content changes are specified.SummaryDifference0.1%
- Check58 days agoChange DetectedAdded a new Publications entry detailing a Lancet Oncology study (DeLLphi-303) on tarlatamab with a PD-L1 inhibitor as maintenance therapy in extensive-stage SCLC; no deletions were present.SummaryDifference4%
Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.